Emcure Pharma IPO (Emcure Pharmaceuticals Limited IPO)
Emcure Pharma IPO open for bidding on 3rd July 2024, and ends on 5th July 2024.
Emcure Pharmaceuticals Limited, established in 1983, is an Indian pharmaceutical company engaged in developing, manufacturing, and globally marketing a wide range of products. Their portfolio includes orals, injectables, and biotherapeutics. Emcure operates in over 70 countries, with significant presence in India, Europe, and Canada. Emcure is a leader in gynecology and HIV antivirals, ranking 13th in the domestic market by sales in FY 2024.
Emcure’s products include branded generics, APIs, and biotechnology products. The company has a robust R&D infrastructure and a well-established pan-India sales and distribution network.
Looking ahead, Emcure aims to increase market share by leveraging its product portfolio and expanding its sales and marketing team. They plan to invest in R&D and manufacturing, and pursue strategic acquisitions and partnerships to drive growth. The focus will be on promoting brand efficacy and safety to boost sales.
For more details refer to Emcure Pharma IPO RHP and Emcure Pharma IPO Pulse Score
Emcure Pharma IPO Details
| IPO Date | 3rd July 2024 to 5th July 2024 |
| Listing Date | 10th July 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹960 to ₹1008 per share |
| Lot Size | 14 Shares |
| Total Issue Size | 1,94,83,388 shares (aggregating up to ₹1,952.03 Cr) |
| Fresh Issue | 80,54,549 shares (aggregating up to ₹800.00 Cr) |
| Offer for Sale | 1,14,28,839 shares of ₹10 (aggregating up to ₹1,152.03 Cr) |
| Employee Discount | ₹90 per Share |
| Issue Type | Book Built Issue IPO |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| Anchor Investor | 57,79,850(29.67%) |
| QIB | 37,62,896(19.31%) |
| NII | 29,49,523(15.14%) |
| bNII | 19,66,349(10.1%) |
| sNII | 9,83,174(5.04%) |
| Retail | 68,82,219(35.32%) |
| Employees | 1,08,900(0.55%) |
| Total | 1,94,83,388(100%) |
Emcure Pharma IPO Timeline
| IPO Open | 3rd July 2024 |
| IPO Close | 5th July 2024 |
| Basis Of Allotment | 8th July 2024 |
| Initiation of Refunds | 9th July 2024 |
| Credit of Shares to Demat | 9th July 2024 |
| Listing Date | 10th July 2024 |
Fundamentals
Data as of 31st March 2024
| Market Cap | ₹ 19,029.89 Cr | P/E Ratio- Pre IPO | 34.55 |
| RoNW | 16.87% | P/E Ratio- Post IPO | 36.07 |
| RoCE | 19.37% | P/B Ratio | 6.18 |
| Debt to Equity | 0.67 | PAT Margin% | 7.86% |
Emcure Pharma IPO Objectives
The company proposes to utilize the Net Proceeds towards the funding of the following objects:
- Repayment and/ or prepayment of all or a portion of certain outstanding borrowings availed by the Company; and
- General corporate purposes
Leave a Reply